The demand for anti-rheumatic drugs in Malaysia has been increasing steadily in recent years.
Customer preferences: Patients suffering from rheumatoid arthritis and other rheumatic diseases are the primary consumers of anti-rheumatic drugs in Malaysia. However, with an aging population and increasing awareness about the benefits of early diagnosis and treatment, the demand for these drugs is expected to rise further in the coming years.
Trends in the market: One of the key trends in the anti-rheumatic drugs market in Malaysia is the growing popularity of biologic drugs. These drugs, which are made from living cells, offer better outcomes and fewer side effects compared to traditional drugs. As a result, they are becoming increasingly preferred by doctors and patients alike. Another trend is the increasing availability of generic drugs, which are more affordable than branded drugs and therefore more accessible to a wider range of patients.
Local special circumstances: One of the unique challenges facing the anti-rheumatic drugs market in Malaysia is the lack of awareness and understanding of rheumatic diseases among the general public. This can lead to delays in diagnosis and treatment, which can have a significant impact on patient outcomes. To address this issue, there is a need for greater public education and awareness campaigns.
Underlying macroeconomic factors: The Malaysian government has made significant investments in healthcare infrastructure and services in recent years, which has helped to improve access to healthcare for the population. This has also contributed to the growth of the anti-rheumatic drugs market, as more patients are able to access diagnosis and treatment. Additionally, the increasing prevalence of rheumatic diseases in Malaysia can be attributed to factors such as changing lifestyles, urbanization, and an aging population. These underlying macroeconomic factors are expected to continue driving the growth of the anti-rheumatic drugs market in Malaysia in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
